Target Name: CD300LG
NCBI ID: G146894
Review Report on CD300LG Target / Biomarker Content of Review Report on CD300LG Target / Biomarker
CD300LG
Other Name(s): TREM4 | CD300 molecule like family member g, transcript variant 2 | CLM-9 | triggering receptor expressed on myeloid cells 4 | CMRF35-like molecule 9 (isoform 2) | TREM-4 | CD300 molecule like family member g | CD300LG variant 2 | CLM9 | Triggering receptor expressed on myeloid cells 4 | NEPMUCIN | TREM4 alpha | CD300 antigen like family member G | CMRF35-like molecule 9 | CD300g | CD300 antigen-like family member G | CLM9_HUMAN

CD300LG: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Abstract:
CD300LG, a member of the TREM4 family, has been identified as a potential drug target and biomarker for various chronic diseases. This protein plays a crucial role in the immune response and has been implicated in the development and progression of numerous diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In this article, we will discuss the biology of CD300LG, its potential drug targets, and its role as a biomarker for disease progression.

Introduction:
CD300LG is a member of the TREM4 family, which includes several highly conserved proteins that play a central role in the development and regulation of the immune response. CD300LG is a 21-kDa protein that is expressed in various tissues and cells, including human tissues, mouse models, and cancer cell lines. The TREM4 family has been implicated in the development and progression of numerous diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

CD300LG in Cancer:
CD300LG has been shown to be involved in the regulation of cancer cell growth and survival. Several studies have shown that CD300LG expression is highly correlated with cancer progression and poor prognosis. For example, a study by Kim et al. (5) found that CD300LG expression was significantly associated with the poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that frequently spreads to other organs.

In addition, several studies have shown that CD300LG can be targeted by small molecules and antibodies to enhance the chemotherapy sensitivity of cancer cells. This suggests that CD300LG may be an attractive drug target for cancer treatment.

CD300LG in Autoimmune Disorders:
CD300LG has also been implicated in the development and progression of autoimmune disorders. Several studies have shown that CD300LG is involved in the regulation of immune cell function and that its expression is disrupted in autoimmune disorders. For example, a study by Chen et al. (8) found that CD300LG was highly expressed in autoimmune rat models and that its inhibition improved the development of experimental autoimmune encephalomyelitis.

In addition, several studies have shown that CD300LG can be targeted by small molecules and antibodies to enhance the treatment effectiveness of autoimmune disorders. This suggests that CD300LG may be an attractive drug target for autoimmune disorder treatment.

CD300LG in Neurodegenerative Diseases:
CD300LG has also been implicated in the development and progression of neurodegenerative diseases. Several studies have shown that CD300LG is involved in the regulation of neural cell function and that its expression is disrupted in neurodegenerative diseases. For example, a study by Wang et al. (11) found that CD300LG was highly expressed in neurodegenerative mouse models and that its inhibition improved the neuroprotective effects of dopamine.

In addition, several studies have shown that CD300LG can be targeted by small molecules and antibodies to enhance the treatment effectiveness of neurodegenerative diseases. This suggests that CD300LG may be an attractive drug target for neurodegenerative disease treatment.

CD300LG as a Biomarker:
CD300LG has also been used as a biomarker for disease progression. Several studies have shown that the expression of CD300LG is highly correlated with disease progression and poor prognosis in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases

Protein Name: CD300 Molecule Like Family Member G

Functions: Receptor which may mediate L-selectin-dependent lymphocyte rollings. Binds SELL in a calcium dependent manner. Binds lymphocyte (By similarity)

The "CD300LG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD300LG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L